| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Mamoru Watanabe | Q110728734 |
| P2093 | author name string | Eiko Saito | |
| Kazuo Ohtsuka | |||
| Masakazu Nagahori | |||
| Toshimitsu Fujii | |||
| Katsuyoshi Matsuoka | |||
| Maiko Kimura | |||
| Kento Takenaka | |||
| P2860 | cites work | Infliximab for induction and maintenance therapy for ulcerative colitis | Q28285876 |
| Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study | Q31004717 | ||
| Cyclosporine in severe ulcerative colitis refractory to steroid therapy | Q34060783 | ||
| Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study | Q34187731 | ||
| Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis | Q34213109 | ||
| Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up | Q34506976 | ||
| The role of tacrolimus in inflammatory bowel disease: a systematic review | Q34565098 | ||
| Effects of oral tacrolimus as a rapid induction therapy in ulcerative colitis | Q35069498 | ||
| A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis | Q35768942 | ||
| Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease | Q36700682 | ||
| Colon Mucosa Exhibits Loss of Ectopic MUC5AC Expression in Patients with Ulcerative Colitis Treated with Oral Tacrolimus | Q36830507 | ||
| Infliximab or cyclosporine for acute severe ulcerative colitis: a retrospective analysis. | Q37957998 | ||
| Oral tacrolimus as maintenance therapy for refractory ulcerative colitis--an analysis of outcomes in two London tertiary centres | Q38102458 | ||
| Tacrolimus induction followed by maintenance monotherapy is useful in selected patients with moderate-to-severe ulcerative colitis refractory to prior treatment. | Q38229318 | ||
| Two cases of fatal Pneumocystis jirovecii pneumonia as a complication of tacrolimus therapy in ulcerative colitis--a need for prophylaxis | Q42788630 | ||
| Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus | Q43024877 | ||
| Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus | Q43154081 | ||
| Oral tacrolimus for the treatment of refractory inflammatory bowel disease in the biologic era. | Q43497300 | ||
| Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients | Q43611596 | ||
| Immunosuppressant pharmacodynamics on peripheral-blood mononuclear cells from patients with ulcerative colitis | Q44154127 | ||
| Response of refractory colitis to intravenous or oral tacrolimus (FK506). | Q44247090 | ||
| Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease | Q44446912 | ||
| Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis | Q44563336 | ||
| Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients. | Q45831311 | ||
| Local application of tacrolimus in distal colitis: feasible and safe | Q46339652 | ||
| Rectal tacrolimus in the treatment of resistant ulcerative proctitis | Q46398728 | ||
| Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects | Q46511193 | ||
| Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. | Q46543821 | ||
| Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children | Q46793423 | ||
| Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis | Q50267679 | ||
| Topical tacrolimus therapy for antibiotic-refractory pouchitis. | Q50774830 | ||
| Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. | Q50891880 | ||
| A questionnaire-based survey on the diagnosis and management of inflammatory bowel disease in East Asian countries in 2012. | Q51756815 | ||
| Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. | Q53122367 | ||
| Tacrolimus for remission induction in ulcerative colitis: Mayo endoscopic subscore 0 and 1 predict long-term prognosis. | Q53608268 | ||
| Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). | Q54121491 | ||
| ABCB1 Single-Nucleotide Polymorphisms Determine Tacrolimus Response in Patients With Ulcerative Colitis | Q57072058 | ||
| Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial | Q59120396 | ||
| Oral tacrolimus treatment of severe colitis in children | Q63285890 | ||
| FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro | Q69010285 | ||
| Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience | Q81319400 | ||
| Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis | Q83449100 | ||
| Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis | Q83567286 | ||
| Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus | Q85762235 | ||
| Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus | Q86122542 | ||
| Efficacy of salvage therapy and its effect on operative outcomes in patients with ulcerative colitis | Q87155464 | ||
| Long-term comparative efficacy of cyclosporine- or infliximab-based strategies for the management of steroid-refractory ulcerative colitis attacks | Q87420118 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ulcerative colitis | Q1477 |
| P304 | page(s) | 219-26 | |
| P577 | publication date | 2015-07-01 | |
| P1433 | published in | Intestinal research | Q27725964 |
| P1476 | title | Tacrolimus for the Treatment of Ulcerative Colitis | |
| P478 | volume | 13 |
| Q64052770 | A Review of Extraintestinal Manifestations and Complications of Inflammatory Bowel Disease |
| Q64069288 | Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis |
| Q58788974 | Pooled analysis of the comparative efficacy between tacrolimus and infliximab for ulcerative colitis |
| Q64123359 | Pretreatment neutrophil-to-lymphocyte ratio predicts clinical relapse of ulcerative colitis after tacrolimus induction |
| Q88642131 | Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease |
| Q37660726 | Significant contribution of TRPC6 channel-mediated Ca2+ influx to the pathogenesis of Crohn's disease fibrotic stenosis |
| Q98386851 | Simple water-based tacrolimus enemas for refractory proctitis |
| Q47327588 | Updated treatment strategies for intestinal Behçet's disease |
Search more.